1-4 of 4
Shimrit Harlev
Close
Sort by
Journal Articles

Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Ofrat Beyar Katz, Chava Perry, Efrat Luttwak, Inbal Sdayoor, Yael Bar-On, Odelia Amit, Ronit Gold, Yair Herishanu, Noam Benyamini, Sigal Grisariu Greenzaid, Batia Avni, Polina Stepensky, Diana Libster, Dana Yehudai-Ofir, Shimrit Harlev, Liat Sharvit, Tsila Zuckerman, Uri Greenbaum, Irit Avivi, Ron Ram
Journal: Blood
Blood (2022) 140 (Supplement 1): 3816–3817.
https://doi.org/10.1182/blood-2022-165149
Published: 2022
Journal Articles

Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia

Shimrit Harlev, Nashwa Fadaos, Tehila Azoulay, Ronit Leiba, Nurit Horesh, Tsofia Inbar, Netanel A. Horowitz, Inna Tsoran-Rosenthal, Noa Lavi, Eldad J. Dann, Tsila Zuckerman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6534–6535.
https://doi.org/10.1182/blood-2022-166233
Published: 2022
Journal Articles

Clinical Features, Laboratory Characteristics, and Response to Therapy in Patients with Acute Undifferentiated Leukemia

Shimrit Harlev, MD PhD, Tehila Azoulay, Margrita Filatov, Galit Sarig, PhD, Ilana Slouzkey, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1505.
https://doi.org/10.1182/blood-2018-99-118033
Published: 2018
Journal Articles

Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse

Yishai Ofran, MD, Chezi Ganzel, MD, Shimrit Harlev, MD PhD, Ilana Slouzkey, PhD, Ofrat Beyar Katz, MD, Michal Hayun, PhD, Mira Kharit, MD, Jacob M. Rowe, MD, Avraham Frisch, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5206.
https://doi.org/10.1182/blood-2018-99-111258
Published: 2018